Welcome to our dedicated page for Lifecore Biomedical SEC filings (Ticker: LFCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lifecore Biomedical, Inc. filings document the reporting obligations of a Nasdaq-listed injectables CDMO that develops, fills and finishes sterile pharmaceutical products and manufactures injectable-grade hyaluronic acid. Its 8-K reports furnish operating results, financial-condition updates and Regulation FD investor presentation materials tied to the company’s CDMO programs and corporate updates.
Proxy and governance filings cover director elections, annual meeting voting, executive compensation, incentive plan matters, shareholder proposal procedures and the company’s fiscal-year change to calendar-year reporting. The filings also reference the company’s common stock and Series A Convertible Preferred Stock within voting and capital-structure disclosures.
Legion Partners and related entities report a significant stake in Lifecore Biomedical, Inc. (LFCR) and update their position details. They collectively may be deemed to beneficially own up to 6,794,595 common shares, representing approximately 17.1% of Lifecore’s common stock, including shares issuable from immediately convertible Series A Preferred Stock and director equity awards.
Legion Partners I beneficially owns 6,196,557 shares and Legion Partners II owns 520,263 shares, both including shares issuable upon conversion of Series A Preferred Stock. The ownership percentages are calculated using 37,509,407 common shares outstanding as of April 29, 2026, plus the shares underlying the preferred stock held by the group.
The group also discloses that on June 30, 2026, Legion Partners I and II delivered written notices to redeem all of their Series A Preferred Stock at the Holder Optional Redemption Price, with Lifecore required to redeem these preferred shares for cash on December 28, 2026. The reporting persons state they have made no Lifecore securities transactions in the previous 60 days and expressly disclaim beneficial ownership of securities they do not directly own.
Lifecore Biomedical received redemption notices for all 49,263 outstanding shares of its Series A Redeemable Convertible Preferred Stock, triggering a required cash redemption of approximately $52.1 million on December 28, 2026, based on a $1,000 per-share price plus accrued dividends.
As of June 30, 2026, the Series A Preferred Stock carried about $0.9 million of accrued and unpaid dividends and a total liquidation value of roughly $50.2 million. If Lifecore does not redeem all shares submitted on December 28, 2026, the unpaid balance will accrue interest at 1% per month.
The company must obtain lender consent under its credit agreements before making redemption payments and is evaluating strategic alternatives, including cash on hand, potential debt or equity financings, and other transactions. As of March 31, 2026, Lifecore reported total liquidity of $38.1 million, including $20.8 million in cash and cash equivalents and $17.3 million of availability under its revolving credit facility.
Kiper Christopher S reported acquisition or exercise transactions in this Form 4 filing.
Lifecore Biomedical director Christopher S. Kiper reported an equity award linked to his board service. He received 25,907 restricted stock units (RSUs), each representing a contingent right to one share of Common Stock, at a stated price of $0.00 per unit. The RSUs vest on the earlier of June 4, 2027 or the first annual stockholder meeting held in 2027, if that meeting occurs at least 50 weeks after June 4, 2026. After this award, Kiper reports 103,482 shares/RSUs directly, while affiliated Legion funds report indirect holdings including 4,084,268 shares held by Legion Partners, L.P. I and 319,286 shares held by Legion Partners, L.P. II. Footnotes state that the economic interest in securities granted for Kiper’s board role belongs to Legion Partners Asset Management and its affiliates.
Lifecore Biomedical director Nelson Obus received an equity grant in the form of restricted stock units. The award covers 25,907 RSUs that convert into common stock on a 1-for-1 basis. These units vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, provided that date is at least 50 weeks after June 4, 2026. Following this grant, Obus holds 164,100 shares of Lifecore Biomedical common stock directly.
Lifecore Biomedical director Jason Aryeh received an equity award of 25,907 shares of common stock as a grant, not an open-market purchase. The award reflects restricted stock units that convert into common stock on a 1-for-1 basis. Following this grant, he directly holds 69,967 shares. The units vest on the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders, provided that meeting occurs at least 50 weeks after June 4, 2026.
Lifecore Biomedical director Joshua Schechter received an equity grant as part of his compensation. On the reported date, he was awarded 25,907 restricted stock units that convert into common stock on a 1-for-1 basis at no cash cost to him.
The grant vests on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. After this award, Schechter directly holds 133,080 shares of Lifecore common stock.
Lifecore Biomedical director Matthew E. Korenberg received a grant of 25,907 shares of common stock in the form of restricted stock units, with no cash paid per share. This award is compensation, not an open-market purchase, and increases his direct holdings to 69,967 shares.
The restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the Lifecore Biomedical annual stockholders meeting first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026.
Director Humberto Calheiros Antunes of Lifecore Biomedical, Inc. reported receiving an award of 25,907 shares of common stock in the form of restricted stock units. The award has no cash exercise price and increases his direct holdings to 72,967 shares after the transaction.
The restricted stock units convert into common stock on a 1-for-1 basis and will vest on the earlier of June 4, 2027 or the date of Lifecore’s 2027 annual stockholders’ meeting, provided that meeting occurs at least 50 weeks after June 4, 2026.
Lifecore Biomedical director Paul Harold Johnson received an equity award of 25,907 restricted stock units that convert into common stock on a 1-for-1 basis. The award is recorded at a price of $0.00 per share as a grant/award acquisition and is held directly.
The units vest on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. Following this grant, Johnson holds 69,967 shares of common stock.